As we mentioned yesterday, we’ll be highlighting the biopharma industry’s work to combat the coronavirus—and we’re starting today with The Wall Street Journal reporting the first vaccine is ready for clinical testing, thanks to BIO member Moderna.
Moderna, which is researching treatments and vaccines for cancer, heart disease, and infectious diseases based on messenger RNA, announced in Davos a partnership with the Coalition for Epidemic Preparedness and Innovations (CEPI) and NIH's National Institute of Allergy and Infectious Diseases (NIAID) to rapidly develop a vaccine.
And they sent vials of the vaccine to the U.S. government yesterday. Moderna produced the vaccine in their Norwood, Massachusetts, facility, a former Polaroid plant, using “repurposed…robotic equipment that was making cancer vaccines tailored to the genetic mutations of patients’ tumors,” with 100 employees working around the clock.
The clinical trial is expected to begin in April. “The institute expects by the end of April to start a clinical trial of about 20 to 25 healthy volunteers, testing whether two doses of the shot are safe and induce an immune response likely to protect against infection,” explains The Wall Street Journal. “Initial results could become available in July or August.”
What they’re saying: “Going into a Phase One trial within three months of getting the sequence is unquestionably the world indoor record. Nothing has ever gone that fast,” said NIAID Director Dr. Anthony Fauci.
Why it matters: Beyond the potential of stopping a pandemic and saving lives? This kind of innovation wouldn’t be possible without a huge financial commitment by biotech companies and their investors—yet policy proposals like an international price index would make it even harder for them to make the investment. Even if this particular coronavirus dies out, there will be another threat in the future—so we must foster an environment in which biotech innovators can continue the R&D needed to develop new cures.
To stay on top of biotech coronavirus news, visit www.bio.org/coronavirus.
More Health Care News:
STAT: New partnership tries to make up for missing drug data in cost-effectiveness analyses
The Institute for Clinical and Economic Review (ICER) is partnering with Aetion, “a startup that analyzes insurance claims and other data mostly for pharmaceutical companies.”
The Daily Iowan: Sen. Chuck Grassley talks prescription drug prices in Coralville
Speaking at a health care event, the Iowa Republican said he expects the Prescription Drug Pricing Reduction Act of 2019, co-authored with Sen. Ron Wyden (D-OR), will pass by May 20.
The New York Times: White House asks Congress for billions to fight coronavirus
“The request arrived at the same time the Trump administration is proposing cuts to health programs across the government and as health officials across the nation struggle to keep up with costs.”